TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19583868

Group type: EXPERIMENTAL
Intervention: Restricted postoperative IV fluid regime (1.5 L/24 h)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard postoperative IV fluid regime (2.5 L/24 h)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 17972615

Group type: EXPERIMENTAL
Intervention: Closed-circuit isoflurane-based anesthesia (CIA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fentanyl/propofol-based anesthesia (FPA)
Number of subjects: 50
Study: 15218314

Group type: EXPERIMENTAL
Intervention: Adjuvant tegafur (TG) 500 mg/m²/day p.o. for 6 months plus four courses of mitomycin C (MMC) 10-20 mg/m² i.v. every 6 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Adjuvant tegafur (TG) plus MMC
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Adjuvant tegafur (TG) plus MMC in low-TS patients
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mitomycin C (MMC) alone in low-TS patients
Number of subjects: 94
Study: 11674935

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotic therapy (IVAT)
Number of subjects: 125
Study: 9758242

Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg daily
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg daily
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 7846741

Group type: EXPERIMENTAL
Intervention: Famotidine (1 mg/kg/day) administered either intravenously or orally at a dose of 0.5 mg/kg twice a day (maximum: 40 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Famotidine (1 mg/kg/day) administered either intravenously or orally
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Famotidine (0.5 mg/kg twice a day for 8 weeks)
Number of subjects: 14
Study: 3072347

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice a day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice a day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketanserin (any dose) in white patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketanserin (any dose) in black patients
Number of subjects: 16
Study: 31775582

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (66 sessions)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no psychotherapy)
Number of subjects: 76
Study: 30941485

Group type: EXPERIMENTAL
Intervention: Objective functional recovery tests (Timed Up and Go test, knee extensor and flexor strength)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Grip strength assessment
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Subjective physical functioning (SF-36 questionnaire)
Number of subjects: 173
Study: 28619305

Group type: EXPERIMENTAL
Intervention: Music listening during waiting and surgical procedure
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 38
Study: 25735039

Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery with capsulotomy and fragmentation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Laser-assisted cataract surgery with only capsulotomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Laser-assisted cataract surgery with fragmentation only
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 67
Study: 23971858

Group type: EXPERIMENTAL
Intervention: Composite strategy using a saphenous vein graft as a venous bridge to distribute LIMA flow to the anterolateral territory
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional strategy with LIMA-to-LAD anastomosis and revascularization of other anterolateral targets with a separated aorto-coronary saphenous vein graft
Number of subjects: 200
Study: 21266215

Group type: EXPERIMENTAL
Intervention: Ambulatory care (outpatient treatment)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Inpatient care (control group)
Number of subjects: 89
Study: 19748694

Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (5 x 5 Gy)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Poor leukocyte response on day 1
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Interval of 10 days or more between radiotherapy and surgery
Number of subjects: 274
Study: 16715021

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage (ML)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 14
Study: 15589715

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional neuroleptic(s)
Number of subjects: 50
Study: 11477511

Group type: EXPERIMENTAL
Intervention: Average weight patient
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Overweight patient
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Obese patient
Number of subjects: 122
Study: 9405909

Group type: EXPERIMENTAL
Intervention: NPL (neutral protamine lispro)
Number of subjects: 12

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 12
Study: 8423746

Group type: EXPERIMENTAL
Intervention: Training group (N = 47)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (N = 11)
Number of subjects: 58
Study: 3301001

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) nasal spray, 1.36 mg/attack
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30914491

Group type: EXPERIMENTAL
Intervention: Health coaching delivered by a respiratory therapist or nurse
Number of subjects: 215

Group type: COMPARATOR
Intervention: Guideline-based usual care (control)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 215
Study: 29023318

Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy (GDHT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Unspecific hypnotherapy (UHT)
Number of subjects: 45
Study: 25600272

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide with 2% nano-hydroxyapatite
Number of subjects: 60

Group type: COMPARATOR
Intervention: 6% hydrogen peroxide without nano-hydroxyapatite
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments (6% HP with and without n-HA)
Number of subjects: 60
Study: 23922054

Group type: EXPERIMENTAL
Intervention: Onartuzumab (IV) at doses between 4 and 30 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Onartuzumab (IV) co-administered with oral erlotinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Onartuzumab (IV)
Number of subjects: 0
Study: 21327460

Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Birth length
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 278
Study: 19608210

Group type: EXPERIMENTAL
Intervention: 150 mg GSE per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg GSE per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18076799

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy using 5‐fluorouracil (5‐FU)
Number of subjects: 167

Group type: COMPARATOR
Intervention: No perioperative chemotherapy (Control)
Number of subjects: 167
Study: 15887535

Group type: EXPERIMENTAL
Intervention: Visual feedback in young persons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual feedback in elderly persons
Number of subjects: 0
Study: 12185407

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9525792

Group type: EXPERIMENTAL
Intervention: Group family education workshop
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Individual family consultation
Number of subjects: 225

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 225
Study: 7697947

Group type: EXPERIMENTAL
Intervention: Single-dose zileuton
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Multiple-dose zileuton
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 16
Study: 2094221

Group type: EXPERIMENTAL
Intervention: 100 mg almitrine bismesylate (Vectarion)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo-pill
Number of subjects: 11
Study: 689020

Group type: EXPERIMENTAL
Intervention: fenoterol-hydrobromide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ritodrin-HCl
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31244693

Group type: EXPERIMENTAL
Intervention: n-3 index
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: n-6/n-3 PUFA ratio
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: n-3 PUFA DHA
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Nervonic acid (n-9 monounsaturated fatty acid)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Tetracosanoic acid (long-chain saturated fatty acid)
Number of subjects: 285
Study: 28514000

Group type: EXPERIMENTAL
Intervention: Extended resection
Number of subjects: 169

Group type: COMPARATOR
Intervention: Standard resection
Number of subjects: 169
Study: 25472753

Group type: EXPERIMENTAL
Intervention: Ilizarov external fixation (IE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dynamic compression plate (PO)
Number of subjects: 40
Study: 23871449

Group type: EXPERIMENTAL
Intervention: Worry induction
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Worry reduction
Number of subjects: 67

Group type: COMPARATOR
Intervention: Neutral control condition
Number of subjects: 67
Study: 21741151

Group type: EXPERIMENTAL
Intervention: Assisted pelvic floor muscle training (APFMT) using Kegelmaster device
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 91
Study: 18042413

Group type: EXPERIMENTAL
Intervention: Millimetre wave therapy (MWT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 80
Study: 16819272

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 50
Study: 12949688

Group type: EXPERIMENTAL
Intervention: Potentiated ethanol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potentiated morphine
Number of subjects: 0
Study: 11041010

Group type: EXPERIMENTAL
Intervention: Concentrated pattern of disconfirming information with processing instructions to focus on similarities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispersed pattern of disconfirming information with processing instructions to focus on similarities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Processing instructions to focus on differences
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific processing instructions)
Number of subjects: 0
Study: 9310224

Group type: EXPERIMENTAL
Intervention: 5‐FU/epi injectable gel (up to 2 cycles of ≤6 treatments)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5‐FU/epi injectable gel (first cycle of treatment)
Number of subjects: 22
Study: 8229537

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2872857

Group type: EXPERIMENTAL
Intervention: Sulphasalazine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31410676

Group type: EXPERIMENTAL
Intervention: Self-adhesive resin composite (SAC) - Vertise Flow (VER)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional resin composite with self-etching adhesive - Filtek Z250 (Z250) / Clearfil SE Bond (CSEB)
Number of subjects: 27
Study: 29750665

Group type: EXPERIMENTAL
Intervention: Interactive distraction
Number of subjects: 213

Group type: COMPARATOR
Intervention: Passive distraction
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Interactive distraction with parent psychoeducation
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Passive distraction with parent psychoeducation
Number of subjects: 213
Study: 27037050

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA + standard care (SC)
Number of subjects: 273

Group type: COMPARATOR
Intervention: placebo + standard care (SC)
Number of subjects: 273
Study: 24923421

Group type: EXPERIMENTAL
Intervention: Gray matter volume (GMV) of the bilateral amygdala
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Interval perception
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Gray matter volume (GMV) of the bilateral temporal cortex
Number of subjects: 264
Study: 24555229

Group type: EXPERIMENTAL
Intervention: Emoxipin (150 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reamberin (400 ml daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mexidol (300 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 21953329

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg/h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 32
Study: 18296904

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 29
Study: 16567174

Group type: EXPERIMENTAL
Intervention: Betamethasone (3 weekly doses starting at 34 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Prenatal steroids (in cohort study)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No prenatal steroids (in cohort study)
Number of subjects: 34
Study: 14653082

Group type: EXPERIMENTAL
Intervention: Losartan (12 weeks treatment)
Number of subjects: 123

Group type: COMPARATOR
Intervention: AT1-positive group
Number of subjects: 123

Group type: COMPARATOR
Intervention: AT1-negative group
Number of subjects: 123
Study: 11029563

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 36

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36
Study: 9252833

Group type: EXPERIMENTAL
Intervention: Rank analysis of covariance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mantel-Haenszel procedure
Number of subjects: 0
Study: 1376705

Group type: EXPERIMENTAL
Intervention: Aspirating catheter
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard perfusion catheter (infused group)
Number of subjects: 38
Study: 3611779

Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic non-pharmacological methods
Number of subjects: 85
Study: 31630347

Group type: EXPERIMENTAL
Intervention: SOVA web-based technology intervention
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resources provided to implement SOVA over 5 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Baseline survey using EBPAS and PBS
Number of subjects: 14
Study: 29853455

Group type: EXPERIMENTAL
Intervention: ADD-ON (tocilizumab + methotrexate)
Number of subjects: 105

Group type: COMPARATOR
Intervention: SWITCH (tocilizumab alone)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Retreatment with tocilizumab
Number of subjects: 105
Study: 27906034

Group type: EXPERIMENTAL
Intervention: Focused information on spirometry in the invitation
Number of subjects: 4356

Group type: COMPARATOR
Intervention: Standard invitation containing practical information
Number of subjects: 4356
Study: 25098373

Group type: EXPERIMENTAL
Intervention: 12-week exercise program (3 sessions/week)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (inactive)
Number of subjects: 37
Study: 22416101

Group type: EXPERIMENTAL
Intervention: Endoscopic transgastric necrosectomy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Surgical necrosectomy
Number of subjects: 22
Study: 20035241

Group type: EXPERIMENTAL
Intervention: 1% tropicamide and 2.5% phenylephrine (TP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1% tropicamide and 1% cyclopentolate (TC)
Number of subjects: 45
Study: 17885779

Group type: EXPERIMENTAL
Intervention: Carvedilol therapy
Number of subjects: 22
Study: 16967785

Group type: EXPERIMENTAL
Intervention: 100 mCi Iodine-131 (high dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 50 mCi Iodine-131 (low dose)
Number of subjects: 40
Study: 14597947

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg 3 times per day)
Number of subjects: 16
Study: 10523009

Group type: EXPERIMENTAL
Intervention: Low dose ACTH-(1-24) stimulation tests (0.1, 0.5, and 1.0 microg/1.73 m2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Insulin hypoglycemia test (0.15 U/kg insulin)
Number of subjects: 9

Group type: COMPARATOR
Intervention: High dose ACTH stimulation test (250-microg ACTH-(1-24))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 8-hour ACTH-(1-24) infusion (250 microg at a constant rate over 8 h)
Number of subjects: 9
Study: 7552477

Group type: EXPERIMENTAL
Intervention: Zidovudine (500 mg/day)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: L-697,661 (50, 300, or 1,000 mg daily)
Number of subjects: 135
Study: 2048700

Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nasotracheal intubation
Number of subjects: 44
Study: 6108901

Group type: EXPERIMENTAL
Intervention: +cyanidanol-3 (Catechin), 2 g/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30877308

Group type: EXPERIMENTAL
Intervention: Maternal Tdap vaccination during pregnancy
Number of subjects: 371

Group type: COMPARATOR
Intervention: Control group (mothers not vaccinated during pregnancy)
Number of subjects: 371
Study: 30561028

Group type: EXPERIMENTAL
Intervention: Ultrasound-aided instruction and practice on musculoskeletal anatomy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no ultrasound assistance during initial learning)
Number of subjects: 49
Study: 27701902

Group type: COMPARATOR
Intervention: Reminder calls
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 201
Study: 24810252

Group type: EXPERIMENTAL
Intervention: Lace-up ankle braces
Number of subjects: 15
Study: 23416015

Group type: EXPERIMENTAL
Intervention: CysC ≤ 95 mg/l and NT-proBNP ≤ 32 pg/ml
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: NT-proBNP and LV diastolic diameter
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Syndecan-4
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CysC
Number of subjects: 68
Study: 23525025

Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 70 mg Alendronate weekly for eight weeks
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: 10 mg Alendronate daily for eight weeks
Number of subjects: 195
Study: 19887957

Group type: COMPARATOR
Intervention: Coxibs
Number of subjects: 130541

Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 130541

Group type: COMPARATOR
Intervention: Etoricoxib
Number of subjects: 130541
Study: 16893712

Group type: EXPERIMENTAL
Intervention: 5 mg warfarin initiation nomogram
Number of subjects: 50

Group type: COMPARATOR
Intervention: 10 mg warfarin initiation nomogram
Number of subjects: 50
Study: 15256610

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Open drainage plus prednisolone
Number of subjects: 383
Study: 11399987

Group type: EXPERIMENTAL
Intervention: HIV voluntary counselling and testing (VCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health information (HI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive serostatus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disclosure of serostatus
Number of subjects: 0
Study: 9438185

Group type: EXPERIMENTAL
Intervention: Patients with current depression
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Patients with depression and comorbid anxiety disorders
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (diurnal variation and suicidal tendencies)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Increase of appetite
Number of subjects: 559

Group type: COMPARATOR
Intervention: Patients without mental disorders
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Negative overall health self-perception and severity of physical illness
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Disability and reason for medical consultation
Number of subjects: 559
Study: 8515827

Group type: EXPERIMENTAL
Intervention: Xantinolnicotinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone
Number of subjects: 0
Study: 3318546

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg body wt.)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Methohexital (1 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Etomidate (0.3 mg/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 50
Study: 28429883

Group type: EXPERIMENTAL
Intervention: Educational pamphlet on health and mood
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 140
Study: 25811797

Group type: EXPERIMENTAL
Intervention: Cognitive/social activities
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Physical activities
Number of subjects: 221
Study: 24716641

Group type: EXPERIMENTAL
Intervention: Corticosteroids (mean daily dose)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Intensive care unit length of stay
Number of subjects: 203
Study: 23777947

Group type: EXPERIMENTAL
Intervention: Warm bupivacaine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Bupivacaine at room temperature
Number of subjects: 59
Study: 20850833

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (12 sessions, 30 minutes each, 3 times weekly)
Number of subjects: 35
Study: 18847313

Group type: EXPERIMENTAL
Intervention: Plerixafor (AMD3100) combined with G-CSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF alone
Number of subjects: 0
Study: 17056965

Group type: EXPERIMENTAL
Intervention: 20 degrees reverse-Trendelenburg position
Number of subjects: 224

Group type: COMPARATOR
Intervention: Horizontal tilt position (Control)
Number of subjects: 224